Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeCamp, M. M.
Right arrow Articles by Jaklitsch, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeCamp, M. M., Jr
Right arrow Articles by Jaklitsch, M. T.
(Chest. 1999;116:466S-469S.)
© 1999 American College of Chest Physicians

Esophagectomy After Induction Chemoradiation*

Malcolm M. DeCamp, Jr, MD, FCCP; Scott J. Swanson, MD, FCCP and Michael T. Jaklitsch, MD, FCCP

* From the Department of Thoracic and Cardiovascular Surgery (Dr. DeCamp), The Cleveland Clinic Foundation, Cleveland, OH; and the Division of Thoracic Surgery (Drs. Swanson and Jaklitsch), Brigham & Women’s Hospital, Boston, MA.

Correspondence to: Malcolm M. DeCamp, MD, FCCP, The Cleveland Clinic Foundation, Department of Thoracic and Cardiovascular Surgery/F25, 9500 Euclid Ave, Cleveland, OH 44195

The definition of a standard therapy for resectable esophageal cancer remains a clinical controversy. In the past decade, a variety of strategies have been developed in an attempt to improve local control and decrease the all too common problem of distant metastases. Preoperative treatment with radiotherapy or chemotherapy has been proved to be feasible, although neither strategy has resulted in improved survival rates. More recently, concurrent, neoadjuvant chemoradiation has been utilized with encouraging pathologic responses. Equally important is the recognition that such aggressive therapy does not lead to worse surgical outcomes. The evidence for the safety, feasibility, and efficacy of induction therapy followed by esophagectomy is presented in the context of developing a rational methodology to allow for the ongoing modification of standards of care in the management of this difficult disease.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero
Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus
Ann. Thorac. Surg., April 1, 2004; 77(4): 1193 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
T. J. Bugno
Radiation Oncology Analysis
Integr Cancer Ther, March 1, 2002; 1(1): 47 - 49.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.